United Therapeutics (UTHR) announced the first clinical xenotransplantation in its EXPAND study of the UKidney in patients with end-stage renal disease. The successful transplant operation was performed at NYU Langone Health.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UTHR:
- United Therapeutics price target raised to $587 from $569 at RBC Capital
- United Therapeutics price target raised to $525 from $500 at H.C. Wainwright
- United Therapeutics price target raised to $447 from $435 at Morgan Stanley
- United Therapeutics: Hold Rating Amid Optimistic Partnership Prospects and Adjusted Revenue Goals
- United Therapeutics Reports Record Q3 2025 Results